A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 microg b.i.d.) as an Active Control.

Trial Profile

A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 microg b.i.d.) as an Active Control.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Formoterol; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top